Home › Schizophrenia › NCT07101094

Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

Real-world Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Aged ≥18 years at index date.
* Have a confirmed diagnosis of schizophrenia before index date.
* Receipt of an initial prescription order for xanomeline and trospium chloride (XT) and plan to fill and initiate such therapy.
* Provide a signed and dated Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written informed consent form (ICF) in accordance with regulatory, local, and institutional guidelines.
* Agree to use an electronic device to record, or provide paper entry of, patient-reported outcomes (in English or Spanish).
* English or Spanish speaking.

Exclusion Criteria:

* Participation in an interventional study within the last 30 days or plan to participate in such study at the time of eligibility screening.
* Evidence of use of XT prior to time of eligibility screening.

About the study

The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy

What is being tested

• xanomeline and trospium chloride (X/T) therapy (drug)

Sponsor: Bristol-Myers Squibb · Participants: 300 · Started: Sep 22, 2025

Contact the study team

• BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · Phone: 855-907-3286

Official record on ClinicalTrials.gov — NCT07101094

Locations in the U.S.

Conditions

• Schizophrenia

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.